SS-31 Peptide Guide: Mitochondrial Repair, Energy & Recovery Explained

SS-31 (Elamipretide) Peptide Guide: Mitochondrial Repair, Energy & Recovery

SS-31, also known as Elamipretide, is a mitochondrial-targeting peptide studied for its ability to improve cellular energy production, reduce oxidative stress, and support tissue recovery. Unlike many peptides that influence signaling pathways, SS-31 works directly at the mitochondrial level to restore function and efficiency.

View SS-31 Dosage →

In This Breakdown

What Is SS-31? How It Works Potential Benefits What to Expect Stacking Considerations SS-31 vs Similar Peptides Myth vs Reality Side Effects Final Takeaway

What Is SS-31?

Type: Mitochondrial-targeting peptide

Primary Role: Cellular energy + repair

Key Target: Cardiolipin (mitochondrial membrane)

Category: Mitochondrial / longevity peptide

SS-31 is designed to target mitochondria directly, specifically binding to cardiolipin — a key component of the inner mitochondrial membrane responsible for energy production.

How It Works

Cardiolipin Protection
Stabilizes mitochondrial membranes

ATP Production
Improves cellular energy output

Oxidative Stress Reduction
Reduces damage from free radicals

Simple Breakdown:
Protect mitochondria → improve energy → reduce damage

Potential Benefits

• Improved cellular energy production
• Reduced oxidative stress
• Enhanced recovery and endurance
• Support for aging-related decline
• Mitochondrial repair and stability

What to Expect

Early Use
Subtle energy and recovery improvements

Weeks 2–4
More consistent energy and endurance

Long-Term Use
Improved resilience and recovery capacity

Stacking Considerations

MOTS-c
Enhances metabolic signaling

Humanin
Supports cellular protection

Simple Stack Logic:
Repair + signal + protect = full mitochondrial support

Longevity Stack Structure

SS-31 Mitochondrial repair + ATP production

MOTS-c Metabolic signaling + energy regulation

Humanin Cell protection + anti-stress signaling

Why This Stack Works

SS-31 restores damaged mitochondria

MOTS-c improves how energy is used

Humanin protects cells from ongoing stress

SS-31 vs Similar Peptides

SS-31
Direct mitochondrial repair

MOTS-c
Metabolic signaling and adaptation

Humanin
Cell protection and anti-stress signaling

Simple Takeaway:
SS-31 = repair
MOTS-c = signal
Humanin = protect

SS-31 vs MOTS-c vs Humanin

SS-31 (Elamipretide)
• Direct mitochondrial repair peptide
• Targets cardiolipin for structural stability
• Improves ATP production and energy output
• Reduces oxidative stress at the source

MOTS-c
• Mitochondrial signaling peptide
• Activates AMPK pathways
• Improves insulin sensitivity and metabolism
• Often described as an “exercise-mimetic”

Humanin
• Mitochondrial-derived protective peptide
• Anti-apoptotic (prevents cell death)
• Supports longevity and cellular survival
• Focuses on stress resistance and protection

Key Difference
SS-31 = repair mitochondria
MOTS-c = signal energy use
Humanin = protect cells from damage

Simple Takeaway:
Fix damaged mitochondria → SS-31
Improve metabolic signaling → MOTS-c
Protect cells from stress → Humanin

Real-World Use Case:
This stack is often discussed in longevity and performance protocols where the goal is improving energy production, reducing cellular stress, and supporting long-term metabolic health.

Myth vs Reality

Myth: It’s a stimulant
Reality: It improves energy at the cellular level

Myth: Results are immediate
Reality: Effects build over time

Side Effects & Considerations

• Limited human data
• Injection site irritation
• Variable response

Final Takeaway

SS-31 stands out because it works directly at the mitochondrial level, helping restore the systems responsible for energy production rather than simply influencing surface-level pathways.

Disclaimer: SS-31 is not FDA-approved and is for research purposes only.

Research & References

Primary Research

• Szeto HH, Schiller PW. Novel Therapies Targeting Inner Mitochondrial Membrane—From Discovery to Clinical Development. Pharmaceutical Research. 2011.
• Szeto HH. First-in-Class Cardiolipin-Protective Compound as a Therapeutic Agent to Restore Mitochondrial Bioenergetics. British Journal of Pharmacology. 2014.
• Zhao K, Zhao GM, Wu D, et al. Cell-Permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane Inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury. Journal of Biological Chemistry. 2004.
• Karaa A, Haas R, Goldstein A, et al. Randomized Dose-Escalation Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy. Neurology. 2018.
• Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure. 2017.

Reviews & Supporting Research

• Reviews describe SS-31 (Elamipretide) as a mitochondria-targeted tetrapeptide that selectively binds to cardiolipin, a phospholipid unique to the inner mitochondrial membrane. This interaction helps stabilize mitochondrial structure, improve ATP production, reduce reactive oxygen species (ROS), and enhance cellular bioenergetics.
• SS-31 has progressed further than most research peptides, completing numerous Phase 1, Phase 2, and Phase 3 clinical trials in conditions including primary mitochondrial disease, heart failure, kidney disease, age-related eye disease, and skeletal muscle disorders. While the biological mechanism is strongly supported and human safety has been extensively evaluated, several late-stage efficacy trials have produced mixed results, and SS-31 has not received FDA approval. [pmc.ncbi.nlm.nih.gov]

Research Note: SS-31 (Elamipretide) is one of the most extensively studied mitochondrial peptides currently available. Unlike many experimental peptides supported primarily by laboratory research, SS-31 has undergone numerous human clinical trials across multiple diseases involving mitochondrial dysfunction. Its mechanism—binding cardiolipin to stabilize the inner mitochondrial membrane and improve cellular energy production—is well established through decades of biochemical and clinical research. However, while studies consistently demonstrate improvements in mitochondrial function and favorable safety, clinical efficacy has varied depending on the disease being studied. As a result, SS-31 remains an investigational therapy, and many claims regarding healthy aging, athletic performance, recovery, or generalized energy enhancement extend beyond the currently established clinical evidence.

Peptide Directory →